Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Peter F A, Mulders"'
Autor:
Dianne Bosch, Malou C. P. Kuppen, Metin Tascilar, Tineke J. Smilde, Peter F. A. Mulders, Carin A. Uyl-de Groot, Inge M. van Oort
Publikováno v:
Cancers, Vol 15, Iss 15, p 3808 (2023)
Background: Manual data collection is still the gold standard for disease-specific patient registries. However, CAPRI-3 uses text mining (an artificial intelligence (AI) technology) for patient identification and data collection. The aim of this stud
Externí odkaz:
https://doaj.org/article/3ef8baa3fd7849e0ad1c4998e46912c0
Autor:
Robin I. J. Merkx, Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk, Peter F. A. Mulders, Sandra Heskamp
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 570 (2022)
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 (225Ac) or the β--emitter lutetium-177 (177Lu) in mice. BAL
Externí odkaz:
https://doaj.org/article/d9cc433e7203440983f0235c2ff4da3e
Autor:
Maudy C. W. Gayet, Anouk A. M. A. van der Aa, Harrie P. Beerlage, Bart Ph Schrier, Maaike Gielens, Roel Heesakkers, Gerrit J. Jager, Peter F. A. Mulders, Hessel Wijkstra
Publikováno v:
Prostate Cancer, Vol 2020 (2020)
Objective. To compare prostate cancer detection rates (CDRs) and pathology results with targeted prostate biopsy (TB) and systematic prostate biopsy (SB) in biopsy-naive men. Methods. An in-patient control study of 82 men undergoing SB and subsequent
Externí odkaz:
https://doaj.org/article/78284e166bc54b9da16d3cc24506bfff
Autor:
Wieke C. H. Visser, Hans de Jong, Sandra Steyaert, Willem J. G. Melchers, Peter F. A. Mulders, Jack A. Schalken
Publikováno v:
Prostate Cancer and Prostatic Diseases, 25, 583-589
Prostate Cancer and Prostatic Diseases, 25, 3, pp. 583-589
Prostate Cancer and Prostatic Diseases, 25, 3, pp. 583-589
Background Molecular biomarker tests are developed as diagnostic tools for prostate cancer (PCa) diagnosis. The SelectMDx (MDxHealth, Nijmegen, The Netherlands) test is a urinary-based biomarker test intended to be used to predict presence of high-gr
Autor:
Wieke C. H. Visser, Hans de Jong, Willem J. G. Melchers, Peter F. A. Mulders, Jack A. Schalken
Publikováno v:
Cancers, Vol 12, Iss 12, p 3790 (2020)
In the diagnosis and prognosis of prostate cancer (PCa), the serum prostate-specific antigen test is widely used but is associated with low specificity. Therefore, blood-, urinary- and tissue-based biomarker tests have been developed, intended to be
Externí odkaz:
https://doaj.org/article/78b7356d7ccf48909e922124e1229417
Autor:
Jeannette C, Oosterwijk-Wakka, Mirjam C A, de Weijert, Gerben M, Franssen, Dimitar R, Kolev, Ton A F J, de Haan, Otto C, Boerman, Peter F A, Mulders, Egbert, Oosterwijk
Publikováno v:
Neoplasia (New York, N.Y.). 32
Sunitinib is an effective treatment for patients with metastatic Renal Cell Carcinoma (mRCC) but ultimately resistance occurs. The aim of this study was to investigate sunitinib resistance in RCCs and to develop therapeutic combination strategies wit
Autor:
Peter F. A. Mulders, Jack A. Schalken, Jelle O. Barentsz, J. P. Michiel Sedelaar, Jurgen J. Futterer, Inge M. van Oort, Elisabeth A. Wierenga, Gisele H. J. M. Leyten
Publikováno v:
International Journal of Molecular Sciences, Vol 14, Iss 6, Pp 11347-11355 (2013)
PCA3 (prostate cancer gene 3) and multiparametric 3 tesla MRI are new promising diagnostic tools in the detection of PCa. Our aim was to study the clinical value of the Progensa PCA3-test: its predictive value for biopsy outcome, Gleason score and MR
Externí odkaz:
https://doaj.org/article/b518b6ebc8da46a39b6b0489afa2220e
Publikováno v:
International Journal of Molecular Sciences, Vol 14, Iss 6, Pp 11402-11423 (2013)
Monoclonal antibody G250 (mAbG250) recognizes a determinant on carbonic anhydrase IX (CAIX). CAIX is expressed by virtually all renal cell carcinomas of the clear cell type (ccRCC), but expression in normal tissues is restricted. The homogeneous CAIX
Externí odkaz:
https://doaj.org/article/664fdd54f31a4adb8b0f7936e7a9410e
Autor:
Peter F. A. Mulders
Publikováno v:
Tijdschrift voor Urologie. 9:2-29
De FUTURE trial is een multicenter RCT naar MRI target biopten (TB’s) bij patienten met negatieve systematische biopten (SB’s) en een verdenking op prostaatkanker. In deze analyse werden adverse events (AE) van drie technieken van TB vergeleken.
Autor:
Peter F. A. Mulders
Publikováno v:
Tijdschrift voor Urologie. 12:71-71